Analyst Expectations for Edwards Lifesciences's Future
Portfolio Pulse from Benzinga Insights
Edwards Lifesciences (NYSE:EW) has received mixed analyst ratings in the last quarter, with 4 bullish, 2 somewhat bullish, 5 indifferent, and 1 somewhat bearish. The average price target among these analysts is $78.33, which is higher than the current price of $65.75, suggesting an upside. However, this target is a 12.86% decrease from the previous target of $89.89. Analysts' ratings are based on various data sources, including company calls, financial statements, and insider information.
November 28, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences has a mixed outlook from analysts, with a current average price target of $78.33, indicating potential upside from the current price of $65.75 but a decrease from the previous target of $89.89.
The average price target suggests analysts believe the stock has upside potential, which could lead to a positive short-term impact on the stock price. However, the decrease in the target price from the previous average indicates a tempered expectation, which may moderate the positive impact. The mixed ratings with a majority being bullish or indifferent suggest a cautious optimism.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100